{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=8&state=Texas",
    "query": {
      "state": "Texas",
      "city": "Houston",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 22473,
    "total_pages": 2248,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=9&state=Texas&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=7&state=Texas&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T10:49:49.836Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05310071",
      "title": "A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Aducanumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 1027,
      "start_date": "2022-06-02",
      "completion_date": "2024-08-12",
      "has_results": true,
      "last_update_posted_date": "2025-04-23",
      "last_synced_at": "2026-11-01T10:49:49.836Z",
      "location_count": 130,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 107 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05310071"
    },
    {
      "nct_id": "NCT03701334",
      "title": "A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Early Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Endocrine Therapy (ET)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 5101,
      "start_date": "2018-12-07",
      "completion_date": "2030-05-29",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-01T10:49:49.836Z",
      "location_count": 73,
      "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03701334"
    },
    {
      "nct_id": "NCT05458609",
      "title": "Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "Lemborexant 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 8,
      "start_date": "2023-02-09",
      "completion_date": "2024-01-30",
      "has_results": true,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-11-01T10:49:49.836Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05458609"
    },
    {
      "nct_id": "NCT04655404",
      "title": "A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "High Grade Glioma",
        "Diffuse Intrinsic Pontine Glioma"
      ],
      "interventions": [
        {
          "name": "Larotrectinib",
          "type": "DRUG"
        },
        {
          "name": "Larotrectinib surgical",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 15,
      "start_date": "2021-04-08",
      "completion_date": "2036-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-11-01T10:49:49.836Z",
      "location_count": 10,
      "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04655404"
    },
    {
      "nct_id": "NCT04274738",
      "title": "A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Waldenstrom's Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Mavorixafor",
          "type": "DRUG"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "X4 Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2020-04-30",
      "completion_date": "2022-10-31",
      "has_results": false,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-11-01T10:49:49.836Z",
      "location_count": 4,
      "location_summary": "Denver, Colorado • Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04274738"
    },
    {
      "nct_id": "NCT07687238",
      "title": "The Social Needs Assistance for Hospitalized Kids Trial",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Social Needs",
        "Health-Related Social Needs",
        "Social Determinants of Health (SDOH)",
        "Social Needs Status",
        "Conditions Influencing Health Status",
        "Navigation"
      ],
      "interventions": [
        {
          "name": "Active Assistance by Navigators",
          "type": "OTHER"
        },
        {
          "name": "Passive Referral",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1880,
      "start_date": "2026-09",
      "completion_date": "2030-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-01T10:49:49.836Z",
      "location_count": 6,
      "location_summary": "Oakland, California • San Francisco, California • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07687238"
    },
    {
      "nct_id": "NCT04500548",
      "title": "Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Constitutional Mismatch Repair Deficiency Syndrome",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Lynch Syndrome",
        "Recurrent Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Neuroblastoma",
        "Recurrent Primary Central Nervous System Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Neuroblastoma",
        "Refractory Primary Central Nervous System Neoplasm",
        "Xeroderma Pigmentosum"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "12 Months to 25 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-05-11",
      "completion_date": "2022-06-21",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-11-01T10:49:49.836Z",
      "location_count": 7,
      "location_summary": "Palo Alto, California • Aurora, Colorado • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04500548"
    },
    {
      "nct_id": "NCT00726830",
      "title": "Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Lymphoproliferative Disorder",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Pain",
        "Precancerous Condition",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "methadone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "morphine sulfate",
          "type": "DRUG"
        },
        {
          "name": "oxycodone hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2009-03",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2020-09-24",
      "last_synced_at": "2026-11-01T10:49:49.836Z",
      "location_count": 2,
      "location_summary": "Spartanburg, South Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00726830"
    },
    {
      "nct_id": "NCT05079919",
      "title": "A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Olezarsen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 617,
      "start_date": "2021-10-25",
      "completion_date": "2025-07-08",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-11-01T10:49:49.836Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Chula Vista, California + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05079919"
    },
    {
      "nct_id": "NCT05648500",
      "title": "A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lupus Erythematosus, Systemic"
      ],
      "interventions": [
        {
          "name": "Cenerimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Viatris Innovation GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 470,
      "start_date": "2022-12-13",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-01T10:49:49.836Z",
      "location_count": 22,
      "location_summary": "Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more",
      "locations": [
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "DeBary",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05648500"
    }
  ]
}